Date of Publication: 02-Mar-2026
INTELLIGENCE OVERVIEW
Agency: EMA
The European Medicines Agency (EMA), through its Committee for Medicinal Products for Human Use (CHMP), adopted a draft concept paper (EMA/CHMP/30023/2026) for public consultation on the development of a reflection paper addressing the non-clinical development and evaluation of Microbiome-based Medicinal Products (MMPs) draft-concept-paper-development. The consultation period runs from 02 March 2026 to 30 April 2026. This initiative acknowledges the rapid scientific and commercial growth of microbiome therapeutics and the absence of dedicated regulatory guidance tailored to their unique characteristics.
MMPs include live or non-living microorganisms or their derivatives intended to modulate the human microbiome in diseases such as immune disorders, infections, metabolic conditions, and certain cancers. While these products are regulated under existing EU legislation, including Directive 2001/83/EC, there is currently no dedicated guidance addressing their unique non-clinical challenges.
The concept paper highlights gaps in traditional pharmacology and toxicology approaches, particularly concerning biodistribution, persistence, shedding, and the limited relevance of standard animal models. The forthcoming reflection paper aims to provide regulatory clarity, promote harmonized evaluation across the EU, reduce unnecessary animal testing, and support innovation while ensuring patient safety.
For developers and regulatory professionals, this initiative marks a significant step toward establishing a structured EU framework for microbiome-based medicinal products.
KEYWORDS: Biotherapeutic Products, Clinical Trials, Product Diversity
REFERENCE: https://www.ema.europa.eu/en/non-clinical-development-evaluation-microbiome-based-medicinal-products-scientific-guideline